Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Leerink Partners reiterated their market perform rating on shares of 2seventy bio (NASDAQ:TSVT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

The acquisition could save Bristol future profit-sharing costs in Abecma, according to Leerink analyst David Risinger. Last year, 2seventy sold all its experimental cell therapies to Regeneron ...

In a note sent to investors Tuesday, Leerink Partners analyst Daina Graybosch ... as 2seventy already divested its R&D assets to Regeneron and Novo Nordisk, and [Bristol Myers Squibb] manufactures ...